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Abstract 
Background: Intra-operative cell salvage (CS) was reported to have no impairment on blood coagulation in low-
bleeding-risk cardiac surgery with cardiopulmonary bypass (CPB), but studies in high-bleeding-risk cardiac surgery are 
limited. The objective of this study is to evaluate the impact of CS on blood coagulation in high-bleeding-risk cardiac 
surgery with CPB.
Methods: One hundred and ten patients were randomly assigned to either with intra-operative CS group (Group 
CS) or without intra-operative CS group (Group C). Study endpoints included the incidence of impairment of blood 
coagulation during perioperative period (peri-op) and the incidence of adverse events during postoperative period 
(post-op). Peri-op was defined as the period from beginning of anesthesia (anesthesia induction) to 24 h after end of 
surgery. Post-op was defined as the period from the end of surgery to 24 h after end of surgery. The types of impair-
ment of blood coagulation included heparin residual, coagulopathy due to low PLT, coagulopathy due to low FIB, 
coagulopathy due to low coagulation factors, hyperfibrinolytic. The sum of above five types was total impairment of 
blood coagulation. Adverse events included excessive bleeding, resternotomy, etc.
Results: The incidence of heparin residual measured both at the end of surgery and during post-op were signifi-
cantly higher in Group CS than in Group C (15.09 vs 4.00, 13.21 vs 2.00 %; p = 0.024, 0.010, respectively). Similarly, 
the incidence of total impairment of blood coagulation at the end of surgery and during post-op were significantly 
higher in Group CS than in Group C (32.08 vs 18.00, 26.42 vs 12.00 %; p = 0.043, 0.040, respectively). The incidence of 
excessive bleeding during post-op was 32.08 % in Group CS compared with 16.00 % in Group C (p = 0.038). Intrigu-
ingly, CS was associated with a significantly increase in the relative risk ratios for heparin residual and excessive bleed-
ing (p = 0.034, 0.049, respectively).
Conclusions: Intra-operative CS could impair blood coagulation in the scenario of high-risk-bleeding cardiac surgery 
with CPB.
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Background
Individuals who undergo cardiac surgery with cardio-
pulmonary bypass (CPB) are often exposed to impaired 
blood coagulation, both as a result of dysfunction of 
platelet (PLT) and circulatory system was primed of large 
volumes of fluid [1, 2]. Blood coagulation would be theo-
retically further impaired when cell salvage (CS) was used 
in this kind of surgery due to its procedure of centrifu-
gation and washing [3, 4]. However, previous literatures 
indicated that CS had no impairment on blood coagula-
tion in low-bleeding-risk cardiac surgery with CPB [5, 6].
High- bleeding-risk cardiac surgery with CPB refers to 
those surgeries with high risk of bleeding due to patients’ 
poor physical condition and long duration and complex-
ity of the surgery [3, 7, 8]. Among 1.25 million patients 
undergoing cardiac surgery all over the world each year, 
a large proportion is with high-bleeding-risk [9].The vol-
ume of autologous blood transfusion was much larger 
in high-bleeding-risk cardiac surgeries with CPB than 
in low-bleeding-risk ones [9, 10]. Studies demonstrated 
that volume of autologous blood transfusion was associ-
ated with the severity of impairment of blood coagulation 
[11–13]. We hypothesized that CS could impair blood 
coagulation when it was used in high-bleeding-risk car-
diac surgery.
To date, parameters related to blood coagulation 
include thromboelastography (TEG) parameters and 
other hematological parameters such as PLT and FIB. 
TEG was reported as one of the best indicators of blood 
coagulation in cardiac surgery with CPB [14–16]. Com-
bination of the test of kaolin-activated sample and the 
test of heparinase-modified kaolin-activated sample was 
reported much better to detect heparin residues [17, 18].
Till now, limited studies existed evaluating the impact 
of CS on blood coagulation in high-bleeding-risk car-
diac surgery with CPB. The aim of this prospective ran-
domized and controlled clinical trial was to fill this gap. 
The primary endpoint of this trial was the incidence of 
impairment of blood coagulation during perioperative 
period (peri-op), which was defined as the period from 
beginning of anesthesia (anesthesia induction) to 24  h 
after end of surgery (Fig.  1). The secondary endpoint 
was the incidence of adverse events during postoperative 
period (post-op), which was defined as the period from 
the end of surgery to 24 h after end of surgery (Fig. 1).
Methods
Patients
This study was approved by the Ethics Committee of 
the Zhejiang Provincial People’s Hospital (RCT ID: 
ChiCTR-TRC-13003268). Patients were enrolled in the 
study after written informed consent was signed. Inclu-
sion and exclusion criteria were shown in Table  1 [3, 7, 
8]. One hundred and ten eligible patients were randomly 
assigned into two groups according to a randomization 
list: cell salvage group (Group CS) and control group 
(Group C). Patients in Group CS were treated with intra-
operative CS while those in Group C without.
CPB
Tranexamic Acid (AMCHA, 30 mg/kg) was infused in all 
patients after anesthesia induction [9]. The CPB was per-
formed using a HL20 heart–lung machine (MAQUET, 
Israel) with an OCTOPUS4 extracorporeal membrane 
oxygenation (Medtronic, USA). The volume of fluid 
primed was 1.8 L, the main ingredient was ringer’s lactate 
Fig. 1 The timeline of events. T1 5 min before beginning of surgery, T2 5 min after heparin was reversed by protamine, T3 at the end of surgery, T4 
at 24 h after end of surgery. Perioperative period (peri-op) the period from beginning of anesthesia to 24 h after end of surgery. Postoperative period 
(post-op) the period from the end of surgery to 24 h after end of surgery. The period of heparinization: the period from blood anticoagulated by 
heparin to heparin were reversed by protamine. The period of non-heparinization: the period from beginning of surgery to blood anticoagulated by 
heparin + the period from heparin were reversed by protamine to end of surgery
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solution, along with a small amount of albumin and man-
nitol. Anticoagulation was achieved with heparin to main-
tain an activated clotting time (ACT) above 480 s. After 
separation from CPB, heparin was reversed by protamine 
to a target-ACT of range from 90 to 110 % of base value.
Autologous blood transfusion
In Group CS, shed blood from wound and mediastina 
were sucked into the cell saver reservoir (Haemonetics, 
USA, volume of disposable centrifuge bowl is 125  mL) 
after anticoagulated by heparin saline during the period 
of non-heparinization (Fig.  1). The heparinised saline 
contain 25,000  IU of heparin in 1  L of 0.9  % saline at a 
rate of 100 mL/h. At the end of CPB, residual blood in the 
CPB circuit was directly sucked into the reservoir. After 
being filtrated, centrifugated, washed and concentrated, 
the recovered blood turned into autologous blood (autol-
ogous red blood cell suspension), which was transfused 
back to the patient immediately. The washing program 
used in the CS involved a 5:1 ratio between the 0.9  % 
saline wash and collection of blood from the operating 
field. All of the autologous blood was transfused back 
to the patients by the end of surgery. In Group C, shed 
blood from wound and mediastina during the period of 
non-heparinization (Fig.  1) were sucked into suction 
apparatus and were discarded. In Group C, at the end of 
CPB residual blood in the CPB circuit were sucked into 
suction apparatus and were discarded. Patients’ bleeding 
during the period of heparinization (Fig. 1) in two groups 
were sucked into the CPB circuit.
Blood transfusion during peri‑op
After heparin was reversed by protamine, allogeneic 
red blood cell (RBC) was used if hemoglobin (HB) was 
lower than 8 g/dL in Group C [3]. In Group CS, alloge-
neic RBC was used only if HB was still lower than 8 g/dL 
after transfused all of the autologous blood. Allogeneic 
fresh-frozen plasma (FFP) and PLT transfusion was used 
during peri-op according to the protocol (showed in the 
seventh and eighth line in Fig. 2 [3, 16, 19]. Patients with 
excessive bleeding during post-op, which was defined as 
the rate of bleeding greater than 300 mL in the first hour 
after surgery or greater than 2  mL/kg/h for 3 consecu-
tive hours, were treated according to the same protocol 
(Fig. 2).
Study variables
Basal and operative characteristics: including age, gender, 
BSA, type of surgery, complications, CPB time, surgical 
time, tracheal intubation time, length of ICU stay, length 
of hospital stay, the volume of residual blood in CPB cir-
cuit, the volume of intra-operative blood loss, the volume 
of mediastina tube drainage (MTD) in 6 and 24  h after 
surgery, intra-operative dosage of heparin and protamine. 
The volume of intra-operative blood loss was calculated 
as the volume sucked into cell saver reservoir minus the 
volume of heparin saline for anticoagulation in Group CS 
or the volume sucked into suction apparatus in Group C.
Volume of blood transfusion during peri-op: including 
the volume of autogenous blood in Group CS, the volume 
of allogeneic blood (RBC, PLT and FFP) in two groups.
Hematological parameters during peri-op: includ-
ing general parameters and parameters related to blood 
coagulation. General parameters included RBC and HB. 
Parameters related to blood coagulation included TEG 
parameters (Haemonetics, USA), PLT and FIB. TEG 
parameters included R value (R-TEG and R-h-TEG), MA 
and LY 30. R (reaction time, normal range from 10 to 
19 min) represents the time to initiation of clot formation. 
R-TEG and R-h-TEG are the R value of test of kaolin-acti-
vated sample and heparinase-modified kaolin-activated 
sample, respectively; MA (maximum amplitude, normal 
range from 54.5 to 72.5  mm) represents the maximum 
Table 1 Inclusion and exclusion criteria of patients
Eligible patient must meet opportunity of surgery and type of surgery and 
characteristics of patient at the same time
Multiple valves replacement aortic valves replacement + mitral valve 
replacement
Bentall aortic valve replacement + ascending aorta and aortic root replacement
Reoperation not the first time single or multiple valve replacement
BSA body surface area, TEG thromboelastography, HB hemoglobin, PLT platelets, 
Cr creatinine
Inclusion criteria Exclusion criteria
Opportunity of 
surgery




Type of surgery Multiple valves 
replacement
The first time single 
valve replacement
Bentall
Reoperation (at least 1 







Liver Child–Pugh B 
or C
R (TEG) >10 min;
HB <13 g/dL (male) or 
12 g/dL (female)
PLT <50 × 109/L
Drug with-
drawal <3 days 
(Aspirin) or 7 days 
(Clopidogrel)  
(at least 2 items 
above 8 items must 
be met)
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clot strength; LY30 (lysis rate-30, normal range from 0 to 
7.5 %) represents the rate of cloth lysis 30 min after MA. 
Venous blood was tested at the following four time points 
or anytime when excessive bleeding occurred during post-
op: at the time of after anesthesia induction and 5  min 
before beginning of surgery (T1), 5 min after heparin was 
reversed by protamine during surgery (T2), at the end of 
surgery (T3) and at 24 h after end of surgery (T4) (Fig. 1).
Impairment of blood coagulation during peri-op: 
impairment of blood coagulation was diagnosed accord-
ing to the test results of hematological parameters related 
to blood coagulation (showed in the seventh and eighth 
line in Fig.  2). Impairment of blood coagulation were 
classified into five types: heparin residual, coagulopathy 
due to low PLT (decreasing of PLT results in hypocoag-
ulability), coagulopathy due to low FIB (shortage of FIB 
results in hypocoagulability), coagulopathy due to low 
coagulation factors (shortage of other coagulation fac-
tors except for factor results in hypocoagulability) and 
hyperfibrinolytic (showed in the seventh and eighth line 
in Fig. 2) [17, 19]. The sum of above five types was total 
impairment of blood coagulation.
Fig. 2 The processing protocol of excessive bleeding during post-op. Once excessive bleeding was diagnosed, patients received treatment based 
on the results of the tests in the TEG, PLT and FIB. First hour: in the first hour after surgery, hour × 3: for 3 consecutive hours. TEG kaolin-activated 
TEG, h-TEG heparinase-modified kaolin-activated TEG, R reaction time, R-TEG R value in TEG, R-h-TEG R value in h-TEG, MA maximum amplitude, LY30 
lysis index at 30 min, PLT platelets, FFP fresh-frozen plasma, FIB fibrinogen, AMCHA tranexamic acid
Page 5 of 10Shen et al. J Transl Med  (2016) 14:228 
Adverse events during post-op: including excessive 
bleeding, resternotomy, cardiovascular failure, severe 
arrhythmias, myocardial infarction, infection, renal fail-
ure, respiratory failure, epileptic syndrome, cognitive 
decline and death.
Statistical analysis
Data are presented as mean (standard deviation, SD) for 
continuous parametric values, or as numbers with per-
centage for categorical data. For continuous data, the 
two-sample two-sided Student’s t test or the Wilcoxon 
Rank-Sum two-sample two-sided test was used. For cat-
egorical data, the χ2 test or Fisher’s exact-test was used. 
Considering some variables may influence relevant clini-
cal outcomes potentially, the logistic regression model 
was used to analyze the outcomes in Table 4. Odds ratios 
(ORs) resulting from logistic regression analysis were 
used to estimate relative risk (RR) ratios. Data analysis 
was performed using SAS statistical software (version 
9.1; SAS Institute Inc., Cary, NC, USA). P value of less 
than 0.05 was considered as statistically significant.
Results
Basal and operative characteristics
Of the total 110 patients randomized between April 2013 
and September 2014, 55 were allocated to Group CS and 
55 to Group C (Fig. 3). There was no difference between 
two groups in the listed variables (Table 2).
Blood transfusion during peri‑op
The mean volume of autologous blood transfusion in 
Group CS was 4.13  U (0.31  U). The proportion of allo-
geneic RBC transfusion during peri-op was 41.51  % in 
Group CS versus 78.00 % in Group C. The mean volume 
of allogeneic RBC transfusion during peri-op was 2.66 U 
in Group CS versus 5.40  U in Group C. Both the pro-
portion and volume of allogeneic RBC transfusion dur-
ing peri-op were significantly lower in Group CS than in 
Group C (Table 3).
Impairment of blood coagulation during peri‑op
The incidences of heparin residual at T3 and during 
post-op were significant higher in Group CS (15.09 and 
13.21 %) than in Group C (4.00 and 2.00 %), with p value 
as 0.024 and 0.010, respectively (Fig.  4). Similarly, the 
incidences of total impairment of blood coagulation at T3 
and during post-op were significant higher in Group CS 
(32.08 and 26.42 %) than in Group C (18.00 and 12.00 %), 
with p value as 0.043 and 0.040, respectively (Fig. 4). The 
RR value of CS with heparin residual was 6.10. CS was 
associated with an increase in the RR for heparin residual 
(p = 0.034) (Table 5).
Adverse events during post‑op
The incidence of excessive bleeding during post-op were 
significantly higher in Group CS (32.08 %) than in Group 
C (16.00 %) (Table 4). The RR value of CS with excessive 
bleeding was 4.58. CS was associated with an increase in 
the RR for excessive bleeding (p = 0.049) (Table 5).
Discussion
In our present study, significant differences of the inci-
dence of heparin residues and total impairment of blood 
coagulation during peri-op were found between two 
groups. We also found that the incidence of excessive 
bleeding during post-op was significantly higher in group 
CS than in group C. In addition, we found that CS was a 
dependent risk factor for heparin residues and excessive 
bleeding. These results indicate that intra-operative CS 
could impair blood coagulation in the scenario of high-
risk-bleeding cardiac surgery with CPB, which is consist-
ent with our hypothesis.
CPB determines an activation of the coagulation sys-
tem [1, 2]. CS system determines a further activation of 
the coagulation system [3, 4, 20]. The enhanced activa-
tion of the coagulation system induced a strong throm-
bin generation. Thrombin generation directly consumes 
coagulation factors, activates PLT, promotes fibrinolysis, 
lowers fibrinolysis inhibition and stimulates the release of 
tissue plasminogen activator from endothelial cells [20]. 
These conditions were considered as a possible trigger for 
a consumption coagulopathy and hyperfibrinolysis.
In our practice, processing of recovered blood during 
the CS process involves the collection of blood and mix-
ing with heparinised saline, centrifugation of the cells, 
followed by saline washing prior to re-transfusion to the 
patient. The washing program used in the CS involved a 
5:1 ratio between the 0.9 % saline wash and collection of 
blood. This process removes plasma proteins and coagu-
lation factors. In addition, hemodilution during CPB and 
the fluid therapy during post-CPB may result in dilu-
tional coagulopathy [12, 21].
To prevent thrombogenesis during the collection of 
blood, as the standard protocol practiced in our study, 
the heparinised saline containing 25,000  IU of hepa-
rin in 1 L of 0.9 % saline at a rate of 100 mL/h was used. 
Previous studies revealed that after the recovered blood 
processed by the CS system. The autologous blood may 
contain heparin about 500  IU/L [12]. In our study, the 
incidence of heparin residual at the end of surgery were 
15.09 % in Group CS and 4 % in Group C, respectively. 
This result reveals that residual heparin from the CS sys-
tem could worsen the coagulopathy and also is an impor-
tant trigger for the impairment of blood coagulation in 
these patients.
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The dose of heparin in the autologous blood that was 
transfused back to the patient could vary depends on 
the transfusion volume, concentration and drip rate of 
heparinised saline. We found it is very cumbersome in 
clinical practice to estimate the level of heparin in the 
autologous blood. Anticoagulation was commonly moni-
tored with ACT. Clinicians would have to use protamine 
to reverse the residual heparin according to the ACT 
value. The value of ACT may be prolonged by hemodilu-
tion which is very common in this kind of surgery [22]. 
Thus, ACT is a partially reliable bedside method for 
monitoring the adequacy of anticoagulation. Recent stud-
ies revealed that the TEG is a more reliable and sensitive 
method for assessment of the heparinization level after 
the autologous blood transfusion [16, 23]. In our study, 
the R values of heparinase-modified kaolin-activated 
samples (R-h-TEG) were compared with those of kaolin-
activated samples (R-TEG) to assess heparin residual.
The appropriate concentration of the anticoagulant 
heparin saline and the degree of washing performed by 
the CS are vital to preventing the heparin residual from 
the autologous blood. The concentration of the anti-
coagulant heparin saline used was 50,000  IU/L, even 
30,000  IU/L in some report [24]. In our study, although 
the concentration 25,000 IU/L and the degree of washing 
5:1 volume ratio between the 0.9 % saline wash and blood 
were used, the incidence of heparin residual at the end 
of surgery in Group CS was up to 15.09 %. This implies 
that the concentration of 25,000  IU/L may be still risky 
[22]. The solution to this specific problem may be either 
reducing the concentration of anticoagulant heparin 
saline or administering an appropriate dose of protamine 
to reverse heparin depends on the monitoring of TEG. 
However, reducing the concentration of heparin may 
result in thrombogenesis during the collection of blood 
from the operating field. On the other hand, increasing 
the dose of protamine may cause adverse events such as 
allergic reactions. Future studies with a large sample size 
are urgently begged to further evaluate the appropriate 
concentration of the anticoagulant heparin saline.
Literatures indicated that intra-operative CS has no 
impairment on blood coagulation in low-bleeding-risk 
Fig. 3 CONSORT diagram of flow of patients
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cardiac surgery with CPB [5, 6]. In our present study, 
intra-operative CS could impair blood coagulation in the 
scenario of high-risk-bleeding cardiac surgery with CPB. 
Previous studies reported that the volume of autologous 
blood transfused back to the patient in high-bleeding-
risk cardiac surgery with CPB was much larger than in 
low-bleeding-risk cardiac surgery [9, 10]. All types of 
impairment of blood coagulation are associated with the 
volume of autologous blood. The more autologous blood 
transfused, the more severe the impairment of CS on 
blood coagulation to be expected.
To the best of our knowledge, our study is the first pro-
spective randomized controlled clinical trial investigating 
the impact of CS on blood coagulation in high-risk-bleed-
ing cardiac surgery with CPB. As the increasing popular-
ity of the CS, more attention should be focused on the 
patients’ blood coagulation after the autologous blood 
transfusion, especially in the patients in high-bleeding-
risk cardiac surgery with CPB. This study highlighted the 
importance of the blood coagulation monitoring which 
could be overlooked in these situations [24]. We strongly 
Table 2 Patients’ basal and operative characteristics
Data are presented as mean (SD) or number (percentage)
MTD mediastinal tube drainage, patients with resternotomy were not calculated
Variable Group CS (n = 53) Group C (n = 50) P value
Age (years) 50.42 (15.43) 52.53 (15.65) 0.549
 >70 12 (22.64) 13 (26.00) 0.691
Male 27 (50.94) 24 (48.00) 0.765
BSA 1.73 (0.14) 1.73 (0.13) 0.946
 <1.6 m2 5 (9.43) 4 (8.00) 1.000
Surgery type 0.922
 Multiple valve 36 (67.92) 33 (66.00)
 Bentall 8 (15.09) 7 (20.00)
 Reoperations 9 (16.98) 10 (14.00)
Preoperative complication
 Renal dysfunction 19 (35.84) 18 (36.00) 0.987
 Liver insufficiency 9 (16.98) 7 (14.00) 0.676
 Coagulation disorders 15 (28.30) 13 (26.00) 0.793
 HB levels lower (<13 g/dL in male or <12 g/dL in female) 21 (39.62) 23 (46.00) 0.513
17 (32.08) 18 (36.00) 0.674
 PLT levels lower (<50 × 109/L) intake of aspirin or clopidogrel 12 (22.53) 11 (22.00) 0.938
CPB time (min) 136.05 (36.82) 126.65 (25.63) 0.342
Surgical time (min) 302.56 (28.02) 295.94 (22.02) 0.220
Tracheal intubation time (hour) 13.92 (10.83) 13.15 (3.62) 0.434
Length of ICU stay (hour) 19.42 (4.43) 20.42 (4.16) 0.099
Length of hospital stay (day) 22.56 (4.23) 23.38 (4.54) 0.206
Residual blood in CPB circuit 853.67 (50.46) 837.22 (92.53) 0.200
Intra-operative blood loss (mL) 1640.96 (87.73) 1609.03 (137.91) 0.072
MTD (mL)
 In 6 h 333.02 (147.14) 295.03 (152.82) 0.301
 In 24 h 657.78 (272.94) 591.96 (171.53) 0.071
Intra-operative heparin dose (mg) 244.63 (49.82) 241.06 (49.35) 0.778
Intra-operative protamine dose (mg) 428.37 (92.83) 417.36 (92.02) 0.478
Table 3 Allogeneic blood transfusion during peri-op
Data are presented as mean (SD) or number (percentage)
Variable Group CS (n = 53) Group C (n = 50) P value
RBC
 Proportion 22 (41.51) 39 (78.00) 0.0002
 Volume (U) 2.11 (2.66) 5.40 (3.48) <0.0001
FFP
 Proportion 10 (18.87) 9 (18.00) 0.910
 Volume (mL) 118.76 (253.82) 129.00 (284.92) 0.953
PLT
 Proportion 12 (22.64) 10 (20.00) 0.744
 Volume (U) 1.81 (3.56) 1.92 (3.94) 0.916
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recommend application of monitoring of blood coagula-
tion by the TEG combined with kaolin-activated sample 
and heparinase-modified kaolin-activated sample. Our 
experience was valuable for anesthesiologists and sur-
geons to deal with the impairment of blood coagulation 
in this kind of surgery.
One limitation of our study was the evaluation stand-
ard of high-bleeding-risk cardiac surgery. Because there 
is no universal standard so far, the standard we employed 
may need some modification. In addition, double blind 
research method was not adopted in the present study 
Fig. 4 Comparison of impairment of blood coagulation during peri-op between two groups. x-axis type of impairment of blood coagula-
tion, A heparin residual, B coagulopathy for low PLT, C coagulopathy for low FIB, D coagulopathy for low clotting factors, E hyperfibrinolysis, T 
total (A + B + C + D + E). y-axis cases of each type, T1 at the time of after anesthesia induction and 5 min before surgery, T2 5 min after heparin 
was reversed by protamine during surgery, T3 at the end of surgery, post-op during postoperative period, T4 at the time of 24 h after surgery. 
*p = 0.024(T3 − A), 0.043(T3 − T), 0.010 (post-op − A), 0.040 (post-op − T), respectively
Table 4 Relationship of CS with impairment of blood coag-
ulation and adverse events
RR relative risk, CI confidence interval
Variable RR 95 % CI P value
Heparin residual 6.10 1.14–32.60 0.034
Coagulopathy for low PLT 0.61 0.14–2.61 0.509
Coagulopathy for low FIB 1.35 0.40–4.48 0.629
Coagulopathy for low clotting 
factors
0.56 0.09–3.30 0.521
Excessive bleeding 4.58 1.02–18.34 0.049
Myocardial infarction 0.15 0.01–1.99 0.150
Cognitive decline <0.001 <0.001–999.99 0.938
Table 5 Summary of adverse events during post-op
Data are presented as number (percentage)
Variable Group CS (n = 53) Group C (n = 50) P value
Excessive bleeding 17 (32.08) 8 (16.00) 0.038
Resternotomy 3 (5.66) 2 (4.00) 1.000
Cardiovascular failure 6 (11.32) 7 (14.00) 0.682
Severe arrhythmias 
requiring treatment
4 (7.55) 3 (6.00) 1.000
Myocardial infarction 1 (1.89) 4 (8.00) 0.196
Infection 7 (13.21) 6 (12.00) 0.948
 Wound 3 (5.66) 2 (4.00) 1.000
 Others 4 (7.55) 4 (8.00) 1.000
Renal failure 5 (9.43) 4 (8.00) 1.000
Respiratory failure 3 (5.66) 2 (4.00) 1.000
Epileptic syndrome 1 (1.89) 1 (2.00) 1.000
Cognitive decline 0 (0.00) 3 (6.00) 0.111
Death 0 (0.00) 0 (0.00)
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due to objective reasons, which may include some bias. 
This protocol may affect our results. Another limitation 
of present study was the administration of AMCHA 
which lowers fibrinolysis. Accordingly, the incidence of 
hyperfibrinolysis in two groups were lower than usual.
Conclusion
Our preliminary data support a proposal that intra-oper-
ative CS could impair blood coagulation in the scenario 
of high-risk-bleeding cardiac surgery with CPB.
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